Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Immune-checkpoint inhibitors: long-term implications of toxicity
The development of immune-checkpoint inhibitors (ICIs) has heralded a new era in cancer
treatment, enabling the possibility of long-term survival in patients with metastatic disease …
treatment, enabling the possibility of long-term survival in patients with metastatic disease …
Toward personalized treatment approaches for non-small-cell lung cancer
M Wang, RS Herbst, C Boshoff - Nature medicine, 2021 - nature.com
Worldwide, lung cancer is the most common cause of cancer-related deaths. Molecular
targeted therapies and immunotherapies for non-small-cell lung cancer (NSCLC) have …
targeted therapies and immunotherapies for non-small-cell lung cancer (NSCLC) have …
[HTML][HTML] Cancer-associated fibroblast phenotypes are associated with patient outcome in non-small cell lung cancer
Despite advances in treatment, lung cancer survival rates remain low. A better
understanding of the cellular heterogeneity and interplay of cancer-associated fibroblasts …
understanding of the cellular heterogeneity and interplay of cancer-associated fibroblasts …
Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L) 1 blockade in patients with non-small cell lung cancer
Immunotherapy is used to treat almost all patients with advanced non-small cell lung cancer
(NSCLC); however, identifying robust predictive biomarkers remains challenging. Here we …
(NSCLC); however, identifying robust predictive biomarkers remains challenging. Here we …
Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non–small-cell lung cancer with PD-L1 tumor proportion score≥ 50%
PURPOSE We report the first 5-year follow-up of any first-line phase III immunotherapy trial
for non–small-cell lung cancer (NSCLC). KEYNOTE-024 (ClinicalTrials. gov identifier …
for non–small-cell lung cancer (NSCLC). KEYNOTE-024 (ClinicalTrials. gov identifier …
Five-year outcomes with pembrolizumab versus chemotherapy as first-line therapy in patients with non–small-cell lung cancer and programmed death ligand-1 tumor …
Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically based on the primary end point, may be published when key planned co …
report, typically based on the primary end point, may be published when key planned co …
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
DB Doroshow, S Bhalla, MB Beasley… - Nature reviews Clinical …, 2021 - nature.com
Immune-checkpoint inhibitors targeting PD-1 or PD-L1 have already substantially improved
the outcomes of patients with many types of cancer, although only 20–40% of patients derive …
the outcomes of patients with many types of cancer, although only 20–40% of patients derive …
Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a …
Background The first interim analysis of the KEYNOTE-426 study showed superior efficacy
of pembrolizumab plus axitinib over sunitinib monotherapy in treatment-naive, advanced …
of pembrolizumab plus axitinib over sunitinib monotherapy in treatment-naive, advanced …
Five-year outcomes from the randomized, phase III trials checkmate 017 and 057: nivolumab versus docetaxel in previously treated non–small-cell lung cancer
H Borghaei, S Gettinger, EE Vokes… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE Immunotherapy has revolutionized the treatment of advanced non–small-cell
lung cancer (NSCLC). In two phase III trials (CheckMate 017 and CheckMate 057) …
lung cancer (NSCLC). In two phase III trials (CheckMate 017 and CheckMate 057) …
Evolution of systemic therapy for stages I–III non-metastatic non-small-cell lung cancer
JE Chaft, A Rimner, W Weder, CG Azzoli… - Nature reviews Clinical …, 2021 - nature.com
The treatment goal for patients with early-stage lung cancer is cure. Multidisciplinary
discussions of surgical resectability and medical operability determine the modality of …
discussions of surgical resectability and medical operability determine the modality of …